Steward Partners Investment Advisory’s Arbutus Biopharma ABUS Stock Holding History

Steward Partners Investment Advisory’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.2K	Hold	4,000	–	–	﹤0.01%	3435
2026 Q1	$18K	Hold	4,000	–	–	﹤0.01%	3284
2025 Q4	$19.2K	Hold	4,000	–	–	﹤0.01%	3160
2025 Q3	$18.2K	Hold	4,000	–	–	﹤0.01%	3138
2025 Q2	$12.4K	Hold	4,000	–	–	﹤0.01%	3118
2025 Q1	$14K	Hold	4,000	–	–	﹤0.01%	2951
2024 Q4	$13.1K	Hold	4,000	–	–	﹤0.01%	2986
2024 Q3	$15.4K	Hold	4,000	–	–	﹤0.01%	2764
2024 Q2	$12.4K	Hold	4,000	–	–	﹤0.01%	2734
2024 Q1	$10.3K	Hold	4,000	–	–	﹤0.01%	2800
2023 Q4	$10K	Hold	4,000	–	–	﹤0.01%	2717
2023 Q3	$8.12K	Hold	4,000	–	–	﹤0.01%	2671
2023 Q2	$9.2K	Hold	4,000	–	–	﹤0.01%	2593
2023 Q1	$12.1K	Hold	4,000	–	–	﹤0.01%	2469
2022 Q4	$9.32K	Sell	4,000 -1,000	-20%	-$2.39K	﹤0.01%	2562
2022 Q3	$10K	Hold	5,000	–	–	﹤0.01%	2516
2022 Q2	$14K	Sell	5,000 -2,000	-29%	-$5.12K	﹤0.01%	2367
2022 Q1	$21K	Hold	7,000	–	–	﹤0.01%	2328
2021 Q4	$27K	Hold	7,000	–	–	﹤0.01%	2186
2021 Q3	$30K	Hold	7,000	–	–	﹤0.01%	2122
2021 Q2	$21K	Hold	7,000	–	–	﹤0.01%	5015
2021 Q1	$23.3K	Hold	7,000	–	–	﹤0.01%	2406
2020 Q4	$25K	Buy	+7,000	New	+$24.5K	﹤0.01%	1972

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steward Partners Investment Advisory's ABUS Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 4,000 shares worth $19.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3435.

Steward Partners Investment Advisory first reported a position in ABUS in Q4 2020 and has held it in 23 quarters since. The position peaked at $30K in Q3 2021. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Steward Partners Investment Advisory held 4,000 shares of Arbutus Biopharma worth $19.2K as of Q2 2026.
Steward Partners Investment Advisory left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3435 holding.
Steward Partners Investment Advisory first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 23 quarters since.
Steward Partners Investment Advisory's Arbutus Biopharma position peaked at $30K in Q3 2021.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.